SHORT REPORT

Effects of ibuprofen on gene expression in chondrocytes from patients with osteoarthritis as determined by RNA-Seq

Antti Pemmari, Lauri Tuure, Mari Hämäläinen, Tiina Leppänen, Teemu Moilanen, Eeva Moilanen

ABSTRACT

Non-steroidal anti-inflammatory drugs are a widely used symptomatic treatment in osteoarthritis (OA), but their effects on cartilage remain controversial. We studied the effects of ibuprofen on gene expression in chondrocytes from patients with OA using RNA-Seq. Chondrocytes were isolated from cartilage samples of patients with OA undergoing knee replacement surgery, cultured with ibuprofen, and total mRNA was sequenced. Differentially expressed genes were identified with edgeR using pairwise comparisons. Functional analysis was performed using Ingenuity pathway analysis (IPA). Ibuprofen did not induce statistically significant changes in chondrocyte transcriptome when the cells were cultured in the absence of added cytokines. In inflammatory conditions (when the cells were exposed to the OA-related cytokine interleukin (IL)-1β), 51 genes were upregulated and 42 downregulated by ibuprofen with fold change >1.5 in either direction. The upregulated genes included anti-inflammatory factors and genes associated with cell adhesion, while several mediators of inflammation were among the downregulated genes. IPA analysis revealed ibuprofen having modulating effects on inflammation-related pathways such as integrin, IL-8, ERK/MAPK and AMPK-mediated signalling pathways. In conclusion, the effects of ibuprofen on primary OA chondrocyte transcriptome appear to be neutral in normal conditions, but ibuprofen may shift chondrocyte transcriptome towards anti-inflammatory phenotype in inflammatory environments.

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat osteoarthritis (OA) pain but there are some concerns on their effects on chondrocyte biology. OA is characterised by constant low-grade joint inflammation and transient inflammatory exacerbations. The inflammatory nature of the disease is evidenced by the increased production of proinflammatory cytokines, particularly interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumour necrosis factor α (TNFα). They drive the production of catabolic enzymes such as matrix metalloproteinases (MMPs), accelerating joint destruction.

NSAIDs exert their effects by inhibiting the synthesis of prostanooids, particularly prostaglandin E2 (PGE2) by cyclo-oxygenase (COX) enzymes. By altering the balance of proinflammatory and anti-inflammatory mediators in the joint, they have been hypothesised to affect OA pathogenesis. These effects, if any, are however controversial, as both potential benefits (eg, alleviation of joint inflammation and reduction of cartilage catabolism) and harms (eg, impairment of cartilage anabolism and accelerated radiographic joint destruction) have been reported.

We carried out a genome-wide expression analysis on the effects of the NSAID ibuprofen on gene expression in OA chondrocytes in
| Gene          | Name                                      | Function                                                                 | Mean (IL1) | Mean (IL1 + ibu) | FC adj. P |
|--------------|-------------------------------------------|---------------------------------------------------------------------------|------------|-----------------|-----------|
| PPAR3        | Peroxisome proliferator activated receptor gamma | Carbohydrate and lipid metabolism, inflammation                          | 0.3        | 0.9             | 2.87      | 5.0E−06 |
| UMODL1       | Uromodulin like 1                         | Regulation of apoptosis?                                                   | 0.3        | 0.7             | 2.39      | 0.0011  |
| XIRP1        | Xin actin binding repeat containing 1     | Actin binding                                                              | 5.7        | 13.4            | 2.38      | < 1.0E−06 |
| DACT1        | Dishevelled binding antagonist of beta catenin 1 | Regulation of cell cycle and tissue development                          | 4          | 8.4             | 2.1       | < 1.0E−06 |
| CSF2/GM-CSF  | Colony stimulating factor 2=Granulocyte-macrophage colony stimulating factor | Leucocyte differentiation, immune response                                 | 5.2        | 11.2            | 2.09      | < 1.0E−06 |
| PPARGC1B     | PPARG coactivator 1 beta                 | Regulation of transcription                                                | 0.4        | 0.8             | 2.07      | 0.00024 |
| FAM186B      | Family with sequence similarity 186 member B | Cell proliferation, tissue development                                      | 0.4        | 0.7             | 1.92      | 0.0035  |
| SOX17        | SRY-box 17                               | Cell proliferation, tissue development                                      | 3.5        | 6.8             | 1.91      | < 1.0E−06 |
| MTSS1        | MTSS1, I-BAR domain containing            | Cell adhesion                                                              | 6.9        | 12.6            | 1.9       | < 1.0E−06 |
| AKAP6        | A-kinase anchoring protein 6              | Regulation of cell proliferation, cAMP signalling                          | 2.1        | 3.9             | 1.89      | < 1.0E−06 |
| PDE5A        | Phosphodiesterase 5A                     | Regulation of NO signalling                                                | 1.2        | 2.3             | 1.85      | 7.0E−06 |
| RGS2         | Regulator of G protein signalling 2       | Regulation of G protein signalling                                         | 52.1       | 95.9            | 1.85      | < 1.0E−06 |
| CAMK2A       | Calcium/calmodulin dependent protein kinase II alpha | Wnt and TGFβ signalling, NF-κB activation                           | 1.8        | 3.3             | 1.81      | < 1.0E−06 |
| MAP1LC3C     | Microtubule associated protein 1 light chain 3 gamma | Autophagy                                                                  | 0.7        | 1.2             | 1.79      | 3.3E−05 |
| NRG1         | Neuregulin 1                              | Cell differentiation, signal transduction                                  | 0.7        | 1.3             | 1.78      | 5.9E−05 |
| SELE         | Selectin E                               | Inflammation                                                               | 41.3       | 73.5            | 1.78      | < 1.0E−06 |
| FCRLA        | Fc receptor like A                        | Immunoglobulin binding                                                     | 4.2        | 7.4             | 1.76      | < 1.0E−06 |
| DENND3       | DENN domain containing 3                 | Autophagy                                                                  | 14.6       | 25.3            | 1.75      | < 1.0E−06 |
| FCRLB        | Fc receptor like B                        | Immunoglobulin binding                                                     | 0.8        | 1.4             | 1.73      | 3.3E−05 |
| MOXD1        | Monoxygenase DBH like 1                  | Monoamine metabolism                                                      | 123.1      | 210.3           | 1.72      | < 1.0E−06 |
| SPNS2        | Sphingolipid transporter 2               | Lipid transport                                                            | 2.4        | 4.0             | 1.72      | < 1.0E−06 |
| PODXL        | Podocysin like                            | Cell adhesion                                                              | 11.2       | 19.0            | 1.71      | < 1.0E−06 |
| RP1          | RP1, anoxonal microtubule associated      | ?                                                                           | 0.4        | 0.6             | 1.67      | 0.023   |
| IDO1         | Indoleamine 2,3-dioxygenase 1            | Modulation of inflammation and cartilage development                      | 1.3        | 2.1             | 1.65      | 0.0012  |
| SCUBE3       | Signal peptide, CUB domain and EGF like domain containing 3 | TGFβ signalling                                                        | 42.5       | 72.5            | 1.64      | < 1.0E−06 |
| KCNJ15       | Potassium voltage-gated channel subfamily J member 15 | Potassium transport                                                  | 1.3        | 2.2             | 1.63      | 1.0E−06 |
| SERPINE1     | Serpin family E member 1                 | Inhibition of proteolysis                                                 | 455.9      | 748.6           | 1.62      | < 1.0E−06 |
| PSD2         | Pleckstrin and Sec7 domain containing 2   | ?                                                                           | 0.4        | 0.6             | 1.62      | 0.035   |
| LINGO1       | Leucine rich repeat and Ig domain containing 1 | Cell adhesion                                                      | 1.9        | 3.1             | 1.61      | < 1.0E−06 |
| AKNA1        | AKNA domain containing 1                  | ?                                                                           | 0.6        | 1.0             | 1.60      | 0.0048  |
| STRA6        | Stimulated by retinoic acid 6            | Retinol and adipokine binding                                             | 1.9        | 2.9             | 1.59      | 0.00058 |
| ITGAX        | Integrin subunit alpha X                 | Cell adhesion                                                              | 11.0       | 17.4            | 1.58      | < 1.0E−06 |
| KCNN3        | Potassium calcium-activated channel subfamily N member 3 | Potassium transport               | 2.8        | 4.3             | 1.58      | < 1.0E−06 |
| ICAM5        | Intercellular adhesion molecule 5        | Cell adhesion                                                              | 4.5        | 7.2             | 1.58      | < 1.0E−06 |
| FGFR4        | FYVE, RhoGEF and PH domain containing    | Cytoskeleton organisation                                                 | 21.9       | 34.0            | 1.57      | < 1.0E−06 |
| KCNN4        | Potassium calcium-activated channel subfamily N member 4 | Potassium transport               | 6.4        | 10.0            | 1.57      | < 1.0E−06 |
| LRRCS5       | Leucine rich repeat containing 55        | Potassium transport                                                      | 0.8        | 1.3             | 1.56      | 0.0013  |
| CXCR3        | C-X-C motif chemokine receptor 3         | Inflammation                                                               | 0.7        | 1.1             | 1.55      | 0.017   |
| CD24         | CD24 molecule                             | Wnt and MAPK signalling, regulation of inflammation                     | 5.4        | 8.5             | 1.55      | < 1.0E−06 |
| FGR          | FGR proto-oncogene, Src family tyrosine kinase | PI3K-Akt signalling, regulation of inflammation                     | 3.4        | 5.2             | 1.54      | < 1.0E−06 |
Table 1 Continued

| Gene | Name | Function | Mean (IL1) | Mean (IL1 +ibu) | FC adj. P |
|------|------|----------|------------|-----------------|----------|
| PEG10 | Paternally expressed 10 | Inhibition of TGFβ signalling | 23.9 | 36.4 | 1.54 | < 1.0E−06 |
| SIGLEC15 | Sialic acid binding Ig like lectin 15 | Regulation of bone resorption | 1.6 | 2.4 | 1.54 | 0.00024 |
| CPNE2 | Copine 2 | Bone erosion | 18.7 | 28.9 | 1.54 | < 1.0E−06 |
| WNK4 | WNK lysine deficient protein kinase 4 | Ion transport | 4.6 | 7.0 | 1.53 | < 1.0E−06 |
| RTL3 | Retrotransposon Gag like 3 | Regulation of collagen production | 3.3 | 5.0 | 1.53 | < 1.0E−06 |
| RGS3 | Regulator of G protein signalling 3 | Inhibition of MAPK signalling | 65.1 | 99.2 | 1.52 | < 1.0E−06 |
| AOC2 | Amine oxidase, copper containing 2 | Amine metabolism | 68.0 | 102.3 | 1.51 | < 1.0E−06 |
| IL10RA | Interleukin 10 receptor subunit alpha | Regulation of inflammation | 1.0 | 1.6 | 1.51 | 0.0018 |
| PCDH17 | Protocadherin 17 | Cell adhesion | 0.9 | 1.4 | 1.51 | 0.028 |
| GPR158 | G protein-coupled receptor 158 | ? | 1.3 | 1.9 | 1.50 | 0.00017 |
| IL23A | Interleukin 23 subunit alpha | Inflammation | 15.2 | 4.7 | -3.24 | < 1.0E−06 |
| HAS1 | Hyaluronan synthase 1 | Extracellular matrix production | 0.8 | 0.3 | -2.77 | < 1.0E−06 |
| IGFBP4 | Insulin-like growth factor binding protein 4 | Cell proliferation and metabolism | 213.8 | 79.7 | -2.73 | < 1.0E−06 |
| IL6 | Interleukin 6 | Inflammation | 958.4 | 403.8 | -2.49 | < 1.0E−06 |
| PDE3A | Phosphodiesterase 3A | Lipid metabolism | 0.9 | 0.3 | -2.48 | 0.00013 |
| STAT4 | Signal transducer and activator of transcription 4 | Inflammation, regulation of cell proliferation | 2.5 | 1.0 | -2.36 | < 1.0E−06 |
| PCSK1 | Proprotein convertase subtilisin/kexin type 1 | Metabolism | 7.2 | 3.2 | -2.19 | < 1.0E−06 |
| ADAMTS6 | ADAM metallopeptidase with thrombospondin type 1 motif 6 | Extracellular matrix catabolism | 10.5 | 4.9 | -2.18 | < 1.0E−06 |
| HAL | Histidine ammonia-lyase | Histidine catabolism | 1.7 | 0.8 | -2.12 | < 1.0E−06 |
| DNAH17 | Dynein axonemal heavy chain 17 | Cytoskeleton component | 1.0 | 0.5 | -2.06 | 2.00E−06 |
| CSF3 | Colony stimulating factor 3 | Inflammation, regulation of cell proliferation | 19.8 | 9.9 | -2.02 | < 1.0E−06 |
| AREG | Amphiregulin | EGF signalling, regulation of cell proliferation | 2.3 | 1.2 | -2.01 | < 1.0E−06 |
| CA12 | Carbonic anhydrase 12 | Acidity regulation, Regulation of proliferation | 20.9 | 10.5 | -2.00 | < 1.0E−06 |
| INSC | Insctuteable homolog (Drosophila) | Cell differentiation | 0.6 | 0.3 | -1.98 | 0.0011 |
| KCNE5 | Potassium voltage-gated channel subfamily E regulatory subunit 5 | Regulation of potassium transport | 1.3 | 0.6 | -1.94 | 6.00E−06 |
| LDB2 | LIN domain binding 2 | Regulation of transcription | 0.5 | 0.3 | -1.92 | 0.00508 |
| DOK6 | Docking protein 6 | ? | 0.9 | 0.5 | -1.80 | 0.000598 |
| DAW1 | Dynein assembly factor with WD repeats 1 | Dynein assembly | 0.9 | 0.5 | -1.78 | 0.00565 |
| TMEM71 | Transmembrane protein 71 | ? | 1.8 | 1.0 | -1.77 | 2.00E−06 |
| MAMSTR | MEF2 activating motif and SAP domain containing transcriptional regulator | Regulation of transcription | 0.5 | 0.3 | -1.72 | 0.02181 |
| KNDC1 | Kinase non-catalytic C-lobe domain containing 1 | ? | 0.8 | 0.5 | -1.70 | 0.00277 |
| EFHC2 | EF-hand domain containing 2 | Cell proliferation | 0.8 | 0.5 | -1.69 | 0.00474 |
| MEX3A | Ms-3 RNA binding family member A | PI3K-Akt signalling | 0.9 | 0.5 | -1.69 | 0.001905 |
| TGFBI | Transforming growth factor beta induced ECM organisation, chondrocyte differentiation | ECM organisation, chondrocyte differentiation | 127.8 | 80.7 | -1.64 | < 1.0E−06 |
| C3AR1 | Complement C3a receptor 1 | Inflammation | 3.5 | 2.2 | -1.63 | < 1.0E−06 |
| EFEMP1 | EGF containing fibulin like extracellular matrix protein 1 | Inhibition of chondrocyte differentiation | 72.6 | 45.4 | -1.63 | < 1.0E−06 |
| NAMPT | Nicotinamide phosphoribosyltransferase / visfatin | Cartilage catabolism | 596.1 | 368.8 | -1.60 | < 1.0E−06 |
| FOXF1 | Forkhead box F1 | Morphogenesis | 1.2 | 0.8 | -1.60 | 0.000928 |
| AVP1 | Arginine vasopressin induced 1 | MAPK signalling | 39.7 | 24.8 | -1.60 | < 1.0E−06 |
| SEMA3A | Semaphorin 3A | Regulation of inflammation and apoptosis | 98.0 | 61.6 | -1.59 | < 1.0E−06 |
| STC1 | Stanniocalcin 1 | Regulation of cartilage development | 2.0 | 1.3 | -1.59 | 0.002967 |

Continued
normal and inflammatory conditions in vitro by using RNA-Seq.

**METHODS**

Cartilage samples were obtained from 10 patients with OA (mean age 67 years (SEM 3.8 years), 8 females, Kellgren-Lawrence grade 3.7 (SEM 0.15)) undergoing knee replacement surgery in Coxa Hospital for Joint Replacement, Tampere, Finland.

Chondrocytes were isolated by enzyme digestion and seeded on 24-well plates for 24 hours. Thereafter the experiments were started, and the cells were cultured either alone, with ibuprofen (10 µM), with IL-1β (100 pg/mL), or with a combination of ibuprofen and IL-1β for 24 hours. Cell culture, RNA sequencing, RT-PCR and data analysis are described in online supplemental data S1.

**RESULTS**

The effects of ibuprofen on OA chondrocytes in neutral conditions

In the absence of exogenous cytokines, no genes were found to be differentially expressed between chondrocytes cultured with or without ibuprofen when the results were adjusted by false discovery rate.

The effects of ibuprofen on OA chondrocytes in inflammatory conditions

In inflammatory conditions (ie, in the presence of the OA-related cytokine IL-1β), ibuprofen induced the upregulation of 51 genes while 42 were downregulated in a statistically significant manner with a fold change >1.5 into either direction (table 1). All differentially expressed genes are listed in online supplemental tables S2 and S3.

The upregulated genes included anti-inflammatory factors such as peroxisome proliferator-activated receptor gamma (PPARG) and its coactivator PPARGC1B as well as IL-10 receptor subunit alpha. In addition, some genes associated with inflammation, including C-X-C motif chemokine receptor 3 (CXCR3), selectin E (SELE), and granulocyte-macrophage colony stimulating factor (CSF2/GM-CSF) were also upregulated (table 1).

On the other hand, several mediators of inflammation (such as IL23A, IL6 and NAMPT (nicotinamide phosphoribosyltransferase aka visfatin)) were downregulated, as was the catabolic enzyme ADAMTS6 (ADAM metalloproteinase with thrombospondin type 1 motif 6). Insulin-like growth factor-binding protein 4 (IGFBP4), which sequesters IGF and regulates chondrocyte proliferation, was also downregulated. Hyaluronic synthase 1 (HAS1) and stanniocalcin-1 (STC1), previously shown to be upregulated in inflamed OA synovium, were also downregulated by ibuprofen (table 1).

Differential expression of selected inflammation and cartilage-related genes (PPARG, PPARGC1B, CSF2, IL23, HAS1, IGFBP4, ADAMTS6 and IL6) was confirmed with RT-PCR using chondrocytes from a different set of 10 patients (online supplemental figure S4). As expected, IL-1β was shown to strongly increase the synthesis of prostaglandins, and this increase was inhibited by ibuprofen (online supplemental figure S5).

When all genes affected by ibuprofen in a statistically significant manner in the presence of IL-1β were analysed with ingenuity pathway analysis (IPA), activated canonical pathways included several associated with inflammation and cell adhesion such as IL-8, integrin, ERK/MAPK and cAMP-mediated signalling pathways (table 2). Conversely, phosphatase and tensin homolog (PTEN) signalling was inhibited (table 2). Differentially expressed genes included in the significantly activated/inhibited pathways are listed in online supplemental table S6.
Among the genes with FC \( >1.5 \) in either direction, STRING analysis identified IL-6 (which was downregulated by ibuprofen) as a central node in the interaction network (figure 1). Other genes occupying central places include PPARG, granulocyte-macrophage colony-stimulating factor and selectin E (PPARG, CSF2 and SELE respectively, all upregulated by ibuprofen).

### DISCUSSION

Ibuprofen did not have any significant effects on gene expression in primary OA chondrocytes cultured in the absence of added cytokines. This implies that ibuprofen has a neutral effect on chondrocyte transcriptome in non-inflamed joints. In cells treated with IL-1\( \beta \), ibuprofen regulated the expression of both proinflammatory and anti-inflammatory factors and seemed to shift the balance to favour the latter.

Ibuprofen is a widely used non-selective NSAID. Like other NSAIDs, it exerts its effects by inhibiting prostanooids, particularly PGE\(_2\), synthesis by COX-1 and COX-2 enzymes. In addition to their role as mediators of pain, prostanooids such as PGE\(_2\) mediate various inflammatory responses. Prostanoids have also been implicated in the pathogenesis OA by affecting cartilage matrix integrity and proteoglycan degradation as well as chondrocyte dedifferentiation and apoptosis.\(^1\)\(^6\) Cellular effects of prostanoids are mediated through G-protein coupled receptors; many prostaglandin receptor subtypes, particularly DP\(_1\), EP\(_2\), EP\(_4\) and IP\(_\beta\) activate adenylate cyclase leading to increased intracellular levels of the multifunctional second messenger cAMP. By activating protein kinase A and transcription factors such as cAMP response element-binding protein, cAMP also regulates the expression of a number of genes.\(^8\) This pathway offers a possible prostanoid-dependent mechanism for the changes in gene expression seen in the present study. In addition, the IPA analysis showed that ibuprofen regulates several other inflammatory pathways which may mediate its effects on chondrocyte transcriptome by prostanoid dependent or independent manner.

In our data, ibuprofen increased the expression of PPARG and its coactivator 1 beta (PPARGC1B). PPARG expression has been shown to be downregulated in OA cartilage,\(^9\) and PPARG may affect the pathogenesis of OA by suppressing joint inflammation, downregulating the production of catabolic enzymes and inhibiting

---

### Table 2

#### Canonical IPA pathways significantly upregulated or downregulated (z-score \( \geq 2.5 \) or \( \leq -2.5 \)) by ibuprofen in the presence of IL-1\( \beta \)

| Canonical pathway | adj. P     | z-score |
|-------------------|------------|---------|
| Integrin signalling | 4.37E-08  | 4.95    |
| Actin cytoskeleton signalling | 0.0022 | 4.24    |
| PI3K signalling in B lymphocytes | 0.00032 | 3.44    |
| Agrin Interactions at neuromuscular junction | 0.0037 | 3.32    |
| IL-8 signalling | 7.08E-07  | 3.29    |
| ERK5 signalling | 0.0083    | 3.16    |
| Glioblastoma multiforme signalling | 1.32E-06 | 3.14    |
| Paxillin signalling | 4.27E-06 | 3.05    |
| ErbB2-ErbB3 signalling | 0.029 | 3.00    |
| FcRRIIB signalling in B lymphocytes | 0.025 | 3.00    |
| Renal cell carcinoma signalling | 0.0016 | 3.00    |
| Bladder cancer signalling | 6.31E-06 | 3.00    |
| 14-3-3-mediated signalling | 0.0058 | 2.89    |
| PKC\(_\theta\) signalling in T lymphocytes | 0.030 | 2.84    |
| Calcium signalling | 0.0083    | 2.84    |
| Thrombin signalling | 0.0025    | 2.83    |
| CREB signalling in neurons | 0.0019 | 2.83    |
| HGF signalling | 1.15E-06  | 2.83    |
| Non-small cell lung cancer signalling | 0.0029 | 2.83    |
| \(\alpha\)-Adrenergic signalling | 5.37E-06 | 2.71    |
| Endothelin-1 signalling | 0.0098 | 2.68    |
| Mouse embryonic stem cell pluripotency | 0.0052 | 2.67    |
| NF-\(\kappa\)B activation by viruses | 0.00089 | 2.67    |
| Macropinocytosis signalling | 4.27E-07 | 2.67    |
| CXCR4 signalling | 0.0048    | 2.67    |
| p70S6K signalling | 0.0026    | 2.67    |
| cAMP-mediated signalling | 0.0034 | 2.56    |
| ErbB4 signalling | 0.014     | 2.53    |
| Chemokine signalling | 0.013 | 2.53    |
| Actin nucleation by ARP-WASP complex | 0.00078 | 2.53    |
| Regulation of cellular mechanics by calpain protease | 5.25E-05 | 2.53    |
| Synaptic long-term potentiation | 0.00011 | 2.52    |
| Cardiac hypertrophy signalling | 0.00015 | 2.50    |
| ERK/MAPK signalling | 1.91E-05 | 2.50    |
| fMLP signalling in neutrophils | 0.0012 | 2.50    |
| PAK signalling | 0.00013  | 2.50    |
| Rac signalling | 0.026     | 2.50    |
| IL-3 signalling | 0.0018    | 2.50    |
| Acute myeloid leukaemia signalling | 0.0017 | 2.50    |

#### Table 2 Continued

| Canonical pathway | adj. P     | z-score |
|-------------------|------------|---------|
| Telomerase signalling | 0.0011 | 2.50    |
| Wnt/Ca\(^{+}\)pathway | 5.25E-05 | 2.50    |
| PTEN signalling | 0.00087   | -2.67   |

adj. P, False discovery rate (FDR) -adjusted P value; CREB, cAMP response element-binding protein; IL-1\(\beta\), interleukin 1\(\beta\); IPA, ingenuity pathway analysis.
chondrocyte apoptosis. Induction of some proinflammatory factors such as CSF2/GM-CSF by ibuprofen can be regarded as a potentially deleterious effect, as CM-CSF has been shown to promote OA development and pain. To our knowledge, this is the first study linking NSAIDs to GM-CSF production in chondrocytes.

IL6 and IL23A as well as ADAMTS6 (ADAM metallopeptidase with thrombospondin type 1 motif 6) are examples of proinflammatory/catabolic factors that were suppressed by ibuprofen. Ibuprofen downregulated also hyaluronan synthase 1 (HAS1) and stanniocalcin-1 (STC1) both of which have been shown to be upregulated in inflamed OA joints. These data suggest that ibuprofen can, to some extent, ‘normalise’ the phenotype of OA tissue under inflammatory conditions. The potential local roles of this proinflammatory cytokine in OA cartilage appear relatively understudied, but its serum levels in patients with OA have been found to be higher compared with controls. IL-6 is considered a central proinflammatory mediator in OA. HAS1 is one of the three principal enzymes participating in the synthesis of hyaluronan, a central extracellular matrix (ECM) component. It may also promote inflammation by producing pericellular, monocyte-attracting hyaluronan coats. STC1 is a calcium-regulating and phosphate-regulating protein whose effects on cartilage appear to be complex. It may inhibit cartilage development, but its expression in synovial cells has also been linked to slower OA progression.

Integrin signalling was the IPA pathway most strongly activated by ibuprofen. This is interesting, as dysregulated integrin signalling has been implicated in OA pathogenesis. Other significantly upregulated pathways include several linked to inflammation (such as IL-8, NF-κB and MAPK/ERK signalling). Looking at the specific genes included in these pathways and affected by ibuprofen (online supplemental table S6) reveals that these can be mostly considered negative feedback genes rather than the major proinflammatory mediators/effectors of these pathways. Examples include several integrins (ITGAM, ITGAX, ITGB2, ITGB3 and ITGB5) in the IL-8 and NF-κB pathways, growth factors and their receptors (VEGFA, VEGFC, HBEGF and FGFR5) in IL-8 signalling as well as anti-inflammatory MAPK phosphatases and PPAR pathway constituents (DUSP1, DUSP2, DUSP4, PRKAR1A, PRKAR1B, PRKAR2B and PPARγ) in MAPK/ERK signalling.

Intriguingly, PTEN signalling was inhibited by ibuprofen. PTEN is a modulator of phosphoinositide 3-kinase/Akt (PI3K/Akt) signalling with various potential effects including promotion of apoptosis, regulation of cell adhesion and inhibition of cell proliferation. PTEN is upregulated in OA chondrocytes, where it inhibits the production of ECM components, and interventions that inhibit PTEN slow the development of osteoarthritic changes in cartilage. To our knowledge, PTEN has not previously been linked to NSAIDs in cartilage.

Previous studies have investigated the effects of NSAIDs and COX-2 selective inhibitors on cartilage/synovial explants. Both prostaglandin-mediated and prostaglandin-independent effects have been observed; these include, for example, inhibition of chondrocyte apoptosis, reduction of nitric oxide synthesis as well as reduced production of catabolic MMPs on IL-1β stimulation. Our study expands these results by investigating the whole transcriptome of ibuprofen-treated OA chondrocytes and provides a starting point for future studies. In conclusion, ibuprofen alone had no significant effects on gene expression in chondrocytes supporting...
cartilage safety of COX inhibitors in the treatment of OA pain. When used in a setting of joint inflammation, ibuprofen seems to shift chondrocyte transcriptome towards an anti-inflammatory phenotype.

Acknowledgements We thank research coordinator Heli Kupari for her assistance with the cartilage samples. We are also grateful to Ms. Meiju Kukkonen and Mrs. Salla Hietakangas for excellent technical assistance, as well as to Mrs. Heili Määltä for great secretarial help.

Contributors Conceptualisation, methodology: all authors. Formal analysis: AP, TL, MH. Investigation: AP, LT, TL, MH. Writing: AP, EM. Visualisation: AP. Supervision and funding: EM.

Funding This study was supported by grants from Finnish Society of Rheumatology and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital.

Disclaimer The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was approved by the Ethics Committee of Tampere University Hospital, Tampere, Finland (decision reference ETL R16076), and performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patients.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the license their derivative works on different terms, provided the original work is

ORCID iD
Antti Pemmari http://orcid.org/0000-0002-8187-1216

REFERENCES
1 Nakata K, Hanai T, Take Y, et al. Disease-Modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review. Osteoarthritis Cartilage 2018;26:1263–73.
2 Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013;21:16–21.
3 Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation 2002;26:139–42.
4 Gruber HE, Hoelscher GL, Ingram JA, et al. Human annulus cells regulate PAPP-A and IGFBP-4 expression, and thereby insulin-like growth factor bioavailability, in response to proinflammatory cytokine exposure in vitro. Connect Tissue Res 2013;54:432–8.
5 Lambert C, Dubé JL, Gauthier F. Genetic pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane. Arthritis Rheumatol 2014;66:960–8.
6 Hardy MM, Seibert K, Manning PT, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002;46:1789–803.
7 Clapp L, Giembycz M, Heinemann A. Prostanoid receptors (version 2020.2) in the IUPHAR/BPS guide to pharmacology database. IUPHAR/BPS Guide to Pharmacology 2020;2.
8 Rafter VK, Bočko C, Steinbrink K. The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases. Front Immunol 2016;7:123.
9 Alf H, Benderdour M, Mfuna-Endam L, et al. Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarticular cartilage and is downregulated by interleukin-1beta in articular chondrocytes. Arthritis Res Ther 2007;9:R31.
10 Fahmi H, Martel-Pelletier J, Pelletier J-P, et al. Peroxisome proliferator-activated receptor gamma in osteoarthritis. Mod Rheumatol 2011;21:1–9.
11 Conaghan PG, Cook AD, Hamilton JA, et al. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol 2019;15:355–63.
12 Askari A, Naghizadeh MM, Homayoonfar R, et al. Increased serum levimibot UL-17A and J-E; Montell E, et al. with decreased vitamin D3 and increased pain in osteoarthritis. PLoS One 2016;11:e0164757.
13 Wojdasiewicz P, Poniawoski Lukasz A, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflam 2014;2014:1–19.
14 Meran S, Martin J, Luo DD, et al. Interleukin-1β induces hyaluronan and CD44-dependent cell protrusions that facilitate fibroblast-monoocyte binding. Am J Pathol 2013;182:223–40.
15 Wu S, Yoshiko Y, De Luca F. Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis. J Biol Chem 2002;278:5120–7.
16 Wu Y, Li Z, Jia W, et al. Upregulation of stanniocalcin-1 inhibits the development of osteoarthritis by inhibiting survival and inflammation of fibroblast-like synovial cells. J Cell Biochem 2019;120:9768–80.
17 Peters JH, Loreda GA, Benton HP. Is osteoarthritis a ‘fibronectin-integrin imbalance disorder’? Osteoarthritis Cartilage 2002;10:831–5.
18 Iwasa K, Hayashi S, Fujishir et al. PTEN regulates matrix synthesis in adult human chondrocytes under oxidative stress. J Orthop Res 2014;32:231–7.
19 Chen Y, Zhang L, Li E, et al. Long-Chain non-coding RNA HOTAIR promotes the progression of osteoarthritis via sponging miR-20b-PTEN axis. Life Sci 2020;253:117685.
20 Williams A, Smith JR, Allaway D, et al. Carprofen inhibits the release of matrix metalloproteinases 1, 3, and 13 in the secretome of an explant model of articular cartilage stimulated with interleukin 1β. Arthritis Res Ther 2013;15:R223.